Dr. Dominick J Angiolillo, MD, PhD
Claim this profileUniversity of Florida
Studies Coronary Artery Disease
Studies Myocardial Ischemia
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Dominick J Angiolillo, MD, PhD is currently running
Antiplatelet Therapy
for Coronary Artery Disease
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e., switching from prasugrel or ticagrelor to clopidogrel while maintaining aspirin) and b) potent P2Y12 inhibitor monotherapy (i.e., maintaining prasugrel or ticagrelor and dropping aspirin). These strategies have been tested in a number of trials and have led to changes in practice guidelines to consider either one of these strategies as bleeding reduction approaches among ACS patients undergoing PCI. However, comparative assessments between DAPT de-escalation and potent P2Y12 inhibitor monotherapy are lacking.
Recruiting3 awards Phase 44 criteria
Ticagrelor vs Clopidogrel
for Coronary Artery Disease
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel. Although practice recommendations indicate that the use of potent P2Y12 inhibitors (i.e., ticagrelor) may be considered in patients at increased thrombotic risk, they do not recommend routine testing to identify patients with poor response to clopidogrel. The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopidogrel vs ticagrelor) in patients at high risk for high platelet reactivity identified according to the ABCD-GENE score in PCI treated patients also requiring OAC. Up to a total of up to 63 patients are planned to be prospectively enrolled in this investigation which will entail a series of comprehensive pharmacodynamic assessments to reach the study aim.
Recruiting3 awards Phase 44 criteria
More about Dominick J Angiolillo, MD, PhD
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Dominick J Angiolillo, MD, PhD has experience with
- Aspirin
- Clopidogrel
- Rivaroxaban
- Dual Pathway Inhibition
- Ticagrelor
- Ticagrelor 60mg
Breakdown of trials Dominick J Angiolillo, MD, PhD has run
Coronary Artery Disease
Myocardial Ischemia
Coronary Heart Disease
Type 2 Diabetes
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dominick J Angiolillo, MD, PhD specialize in?
Dominick J Angiolillo, MD, PhD focuses on Coronary Artery Disease and Myocardial Ischemia. In particular, much of their work with Coronary Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is Dominick J Angiolillo, MD, PhD currently recruiting for clinical trials?
Yes, Dominick J Angiolillo, MD, PhD is currently recruiting for 2 clinical trials in Jacksonville Florida. If you're interested in participating, you should apply.
Are there any treatments that Dominick J Angiolillo, MD, PhD has studied deeply?
Yes, Dominick J Angiolillo, MD, PhD has studied treatments such as Aspirin, Clopidogrel, Rivaroxaban.
What is the best way to schedule an appointment with Dominick J Angiolillo, MD, PhD?
Apply for one of the trials that Dominick J Angiolillo, MD, PhD is conducting.
What is the office address of Dominick J Angiolillo, MD, PhD?
The office of Dominick J Angiolillo, MD, PhD is located at: University of Florida, Jacksonville, Florida 32209 United States. This is the address for their practice at the University of Florida.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.